Category Archives: Pancreatic Cell

Pancreatic Cell News is an online publication and email newsletter providing updates on the latest pancreatitis, diabetes, and pancreatic cancer research.
Subscribe
Pancreatic Cell News is a weekly newsletter that highlights recent top articles in the field of pancreatic cell research. These articles have been carefully selected from high-impact, peer-reviewed academic journals by our experienced editorial team. We cover topics including pancreatic cell culture, pancreatitis, diabetes, and pancreatic cancer. We also feature the latest industry and policy news alongside job postings and upcoming events to keep scientists current while saving them valuable time.

NR5A2 Transcriptional Activation by BRD4 Promotes Pancreatic Cancer Progression by Upregulating GDF15

Scientists demonstrated that NR5A2 acted as a negative prognostic biomarker in PDAC. NR5A2 silencing inhibited the proliferation and migration abilities of pancreatic cancer cells in vitro and in vivo.
[Cell Death Discovery]
Guo, F., Zhou, Y., Guo, H., Ren, D., Jin, X., & Wu, H. (2021). NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Cell Death Discovery, 7(1), 1–15. https://doi.org/10.1038/s41420-021-00462-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Protection of β-Pancreatic Cells From Dysfunctionality of Insulin Using Vitexin by Apoptosis of INS-1 Cells

The authors explored the possible beneficial effects of vitexin on high glucose-induced cytotoxicity in pancreatic β-cells. The INS-1 pancreatic β-cell line was used in this study.
[Archives of Physiology and Biochemistry]
Zhang, L., Shi, L., Han, J., & Li, Z. (2021). Protection of β-pancreatic cells from dysfunctionality of insulin using vitexin by apoptosis of INS-1 cells. Archives of Physiology and Biochemistry, 0(0), 1–8. https://doi.org/10.1080/13813455.2021.1910714 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Glucotoxicity-Induced Suppression of Cox6a2 Expression Provokes β-Cell Dysfunction via Augmented ROS Production

Investigators analyzed the role of Cox6a2 in pancreatic β-cell function and its pathophysiological significance in diabetes mellitus.
[Biochemical and Biophysical Research Communications]
Nagai, Y., Matsuoka, T., Shimo, N., Miyatsuka, T., Miyazaki, S., Tashiro, F., Miyazaki, J., Katakami, N., & Shimomura, I. (2021). Glucotoxicity-induced suppression of Cox6a2 expression provokes β-cell dysfunction via augmented ROS production. Biochemical and Biophysical Research Communications, 556, 134–141. https://doi.org/10.1016/j.bbrc.2021.03.148 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Role of Stromal Activin A in Human Pancreatic Cancer and Metastasis in Mice

Cultured pancreatic stellate cells were found to secrete high levels of activin A resulting in PDAC cell migration that was abolished by anti-activin A neutralizing antibody.
[Scientific Reports]
Mancinelli, G., Torres, C., Krett, N., Bauer, J., Castellanos, K., McKinney, R., Dawson, D., Guzman, G., Hwang, R., Grimaldo, S., Grippo, P., & Jung, B. (2021). Role of stromal activin A in human pancreatic cancer and metastasis in mice. Scientific Reports, 11(1), 7986. https://doi.org/10.1038/s41598-021-87213-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

An Engineered Ligand Trap Inhibits Leukemia Inhibitory Factor as Pancreatic Cancer Treatment Strategy

The authors engineered a high affinity soluble human leukemia inhibitory factor (LIF) receptor decoy that sequestered human LIF and inhibited its signaling as a therapeutic strategy.
[Communications Biology]
Hunter, S. A., McIntosh, B. J., Shi, Y., Sperberg, R. A. P., Funatogawa, C., Labanieh, L., Soon, E., Wastyk, H. C., Mehta, N., Carter, C., Hunter, T., & Cochran, J. R. (2021). An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy. Communications Biology, 4(1), 1–13. https://doi.org/10.1038/s42003-021-01928-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Schlafen 5 as a Novel Therapeutic Target in Pancreatic Ductal Adenocarcinoma

Investigators provided evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human PDAC. Targeted deletion of SLFN5 resulted in decreased PDAC cell proliferation and suppressed PDAC tumorigenesis in in vivo PDAC models.
[Oncogene]
Fischietti, M., Eckerdt, F., Blyth, G. T., Arslan, A. D., Mati, W. M., Oku, C. V., Perez, R. E., Lee-Chang, C., Kosciuczuk, E. M., Saleiro, D., Beauchamp, E. M., Lesniak, M. S., Verzella, D., Sun, L., Fish, E. N., Yang, G.-Y., Qiang, W., & Platanias, L. C. (2021). Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene, 1–14. https://doi.org/10.1038/s41388-021-01761-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors

The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences®, announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 agonist, in combination with checkpoint inhibition immunotherapy.
[TriSalus Life Sciences]
Press Release
Bookmark

No account yet? Register

0
Share

Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. has announced that the company received a notification from the FDA, stating that, as part of its ongoing review of the company’s Biologic License Application for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.
[Provention Bio, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Mutant KRAS Drives Metabolic Reprogramming and Autophagic Flux in Premalignant Pancreatic Cells

The authors report dynamic metabolic reprogramming in immortalized human non-cancerous pancreatic ductal epithelial cells.
[Cancer Gene Therapy]
Suzuki, T., Kishikawa, T., Sato, T., Takeda, N., Sugiura, Y., Seimiya, T., Sekiba, K., Ohno, M., Iwata, T., Ishibashi, R., Otsuka, M., & Koike, K. (2021). Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Therapy, 1–14. https://doi.org/10.1038/s41417-021-00326-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

SerpinB13 Antibodies Promote β Cell Development and Resistance to Type 1 Diabetes

Investigators showed that inhibiting serpinB13, a cathepsin L protease inhibitor expressed in the pancreatic epithelium, caused in vitro and in vivo cleavage of the extracellular domain of Notch1.
[Science Translational Medicine]
Kryvalap, Y., Jiang, M. L., Kryvalap, N., Hendrickson, C., & Czyzyk, J. (2021). SerpinB13 antibodies promote β cell development and resistance to type 1 diabetes. Science Translational Medicine, 13(588). https://doi.org/10.1126/scitranslmed.abf1587 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Immune-Regulated IDO1-Dependent Tryptophan Metabolism Is Source of One-Carbon Units for Pancreatic Cancer and Stellate Cells

Using in vitro and in vivo pancreatic cancer models, scientists showed that IDO1 expression was highly context dependent, influenced by attachment-independent growth and the canonical activator IFNγ.
[Molecular Cell]
Newman, A. C., Falcone, M., Uribe, A. H., Zhang, T., Athineos, D., Pietzke, M., Vazquez, A., Blyth, K., & Maddocks, O. D. K. (2021). Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. Molecular Cell, 0(0). https://doi.org/10.1016/j.molcel.2021.03.019 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share